Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
Stock
REGN
REGN News & Events
-
Add to Watchlist
Trade REGN Autonomously
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Stock Price Prediction
Technical
Valuation
Financials
Earnings
Should I Buy
News & Events
REGN News
Regeneron Projects $127M R&D Charge for Q2 2026
1d ago
seekingalpha
Alnylam Pharmaceuticals Shares Drop 24%, Yet Optimism Persists
5d ago
Fool
Alnylam Pharmaceuticals Reports Strong Q1 Performance
5d ago
NASDAQ.COM
Intellia Therapeutics Shares Surge 83% Amid Strong Clinical Progress
6d ago
Fool
Supreme Court Rulings Have Significant Implications
Jun 30 2026
Newsfilter
Supreme Court Rulings Have Far-Reaching Implications
Jun 30 2026
CNBC
FDA Selects Seven Drug Companies for PreCheck Pilot Program
Jun 29 2026
seekingalpha
ADMA Biologics Shows Promising Profitability Outlook
Jun 29 2026
NASDAQ.COM
Show More News
REGN Events
No data
REGN Monitor News
Regeneron Projects $127M R&D Charge for Q2 2026
Jul 07 2026
Regeneron Pharmaceuticals reaches 20-day high amid market dynamics
Jul 02 2026
Regeneron faces stock decline after Phase 3 trial results for Fianlimab
May 18 2026
Regeneron Offers Gene Therapy Otarmeni for Free in the U.S.
Apr 29 2026
Regeneron Reports Positive Olatorepatide Trial Results Amid Market Decline
Mar 12 2026
Regeneron reaches 52-week high amid market strength
Jan 07 2026
Regeneron shares rise on positive Lynozyfic trial results
Dec 10 2025
Dupixent Approved in EU for CSU Treatment
Nov 25 2025
Show More Monitor News
REGN Earnings Analysis
Regeneron Earnings Report: Strategic Growth in 2025- Intellectia AI™
5 months ago
Regeneron Earnings Soar in Q3 2025: Key Insights & Growth- Intellectia AI™
8 months ago
Regeneron Pharmaceuticals' Resilient Growth Amid Market Challenges - Intellectia AI™
1 years ago
Regeneron Pharmaceuticals Inc Q3 2024 Earnings Summary
1 years ago
People Also Watch
